These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10321722)

  • 1. The effect of an insulin releasing agent, BTS 67582, on advanced glycation end product formation in vitro.
    Simpson AE; Jones RB
    Life Sci; 1999; 64(16):1427-34. PubMed ID: 10321722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoguanidine inhibits protein browning without extensive Amadori carbonyl blocking.
    Requena JR; Vidal P; Cabezas-Cerrato J
    Diabetes Res Clin Pract; 1993 Jan; 19(1):23-30. PubMed ID: 8472617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced desensitization of the insulinotropic effects of antidiabetic drugs, BTS 67 582 and tolbutamide.
    McClenaghan NH; Ball AJ; Flatt PR
    Br J Pharmacol; 2000 May; 130(2):478-84. PubMed ID: 10807689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of advanced protein glycation by a Schiff base between aminoguanidine and pyridoxal.
    Taguchi T; Sugiura M; Hamada Y; Miwa I
    Eur J Pharmacol; 1999 Aug; 378(3):283-9. PubMed ID: 10493104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenolics from Garcinia mangostana Inhibit Advanced Glycation Endproducts Formation: Effect on Amadori Products, Cross-Linked Structures and Protein Thiols.
    Abdallah HM; El-Bassossy H; Mohamed GA; El-Halawany AM; Alshali KZ; Banjar ZM
    Molecules; 2016 Feb; 21(2):251. PubMed ID: 26907243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin.
    Hou FF; Boyce J; Chertow GM; Kay J; Owen WF
    J Am Soc Nephrol; 1998 Feb; 9(2):277-83. PubMed ID: 9527404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of N epsilon-(carboxyethyl)lysine, one of the methylglyoxal-derived AGE structures, in glucose-modified protein: mechanism for protein modification by reactive aldehydes.
    Nagai R; Araki T; Hayashi CM; Hayase F; Horiuchi S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 May; 788(1):75-84. PubMed ID: 12668073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways.
    Booth AA; Khalifah RG; Todd P; Hudson BG
    J Biol Chem; 1997 Feb; 272(9):5430-7. PubMed ID: 9038143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics.
    Valencia JV; Weldon SC; Quinn D; Kiers GH; DeGroot J; TeKoppele JM; Hughes TE
    Anal Biochem; 2004 Jan; 324(1):68-78. PubMed ID: 14654047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-releasing action of the novel antidiabetic agent BTS 67 582.
    McClenaghan NH; Flatt PR; Bailey CJ
    Br J Pharmacol; 1998 Feb; 123(3):400-4. PubMed ID: 9504379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of advanced glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells.
    Menè P; Pascale C; Teti A; Bernardini S; Cinotti GA; Pugliese F
    J Am Soc Nephrol; 1999 Jul; 10(7):1478-86. PubMed ID: 10405203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.
    Reddy S; Bichler J; Wells-Knecht KJ; Thorpe SR; Baynes JW
    Biochemistry; 1995 Aug; 34(34):10872-8. PubMed ID: 7662668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of advanced glycation end product-associated protein cross-linking.
    Lehman TD; Ortwerth BJ
    Biochim Biophys Acta; 2001 Feb; 1535(2):110-9. PubMed ID: 11341999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism.
    Pugliese G; Pricci F; Romeo G; Pugliese F; Mené P; Giannini S; Cresci B; Galli G; Rotella CM; Vlassara H; Di Mario U
    Diabetes; 1997 Nov; 46(11):1881-7. PubMed ID: 9356040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ilex paraguariensis extracts inhibit AGE formation more efficiently than green tea.
    Lunceford N; Gugliucci A
    Fitoterapia; 2005 Jul; 76(5):419-27. PubMed ID: 15894431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of protein-bound carbonyl groups in the formation of advanced glycation endproducts.
    Liggins J; Furth AJ
    Biochim Biophys Acta; 1997 Aug; 1361(2):123-30. PubMed ID: 9300793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 1,1-dimethyl-2-[2-morpholinophenyl]guanidine fumarate on pancreatic islet function.
    Louchami K; Jijakli H; Sener A; Jones RB; Malaisse WJ
    Eur J Pharmacol; 1998 Jul; 352(2-3):289-97. PubMed ID: 9716366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoferulic acid, a new anti-glycation agent, inhibits fructose- and glucose-mediated protein glycation in vitro.
    Meeprom A; Sompong W; Chan CB; Adisakwattana S
    Molecules; 2013 May; 18(6):6439-54. PubMed ID: 23722732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of nonenzymatic glycation of ribonuclease A leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies.
    Khalifah RG; Todd P; Booth AA; Yang SX; Mott JD; Hudson BG
    Biochemistry; 1996 Apr; 35(15):4645-54. PubMed ID: 8664253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of advanced protein glycation by 8-quinolinecarboxylic hydrazide.
    Miwa I; Tsugawa T; Koyasu K; Terada Y
    Pharmacology; 1996 May; 52(5):314-20. PubMed ID: 8807675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.